REZIPAS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rezipas, and when can generic versions of Rezipas launch?
Rezipas is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in REZIPAS is aminosalicylic acid resin complex. There is one drug master file entry for this compound. Additional details are available on the aminosalicylic acid resin complex profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for REZIPAS?
- What are the global sales for REZIPAS?
- What is Average Wholesale Price for REZIPAS?
Summary for REZIPAS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 151 |
| Patent Applications: | 3,635 |
| DailyMed Link: | REZIPAS at DailyMed |
US Patents and Regulatory Information for REZIPAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | REZIPAS | aminosalicylic acid resin complex | POWDER;ORAL | 009052-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
